HUTCHMED (China) Ltd
HMDCF$2.49B
Mid CapNASDAQBiotechnology🇺🇸North America1.8K employees
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
HMDCF News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
HMPL-523
Primary Immune Thrombocytopenia (ITP)
HMPL-760
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
HMPL-523(300mg PO QD)
Warm Antibody Autoimmune Hemolytic Anemia
surufatinib
Tumors
HMPL-A580
Solid Tumors, Adult
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HMPL-523 | Phase 3 | Primary Immune Thrombocytopenia (ITP) | - | - |
HMPL-760 | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | - | - |
HMPL-523(300mg PO QD) | Phase 3 | Warm Antibody Autoimmune Hemolytic Anemia | - | - |
surufatinib | Phase 2 | Tumors | - | - |
HMPL-A580 | Phase 2 | Solid Tumors, Adult | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply